LENZ Therapeutics shares are trading lower after the company reported mixed Q1 financial results. Also, Piper Sandler downgraded the stock from Overweight to Neutral and lowered its price target from $39 to $12.

Benzinga Newsdesk www.benzinga.com Negative 96.1%

Neg 96.1% Neu 0% Pos 0%

Comments

No comments yet. Be the first!